Low HER2 Expressing Breast Cancer Patients Respond Preferentially To Apthera’s NeuVax

Results were announced from analysis of a randomized safety and efficacy clinical trial studying NeuVax (E75) in the adjuvant treatment of early-stage (node-positive and high risk node-negative), HER2-positive breast cancer.

More: continued here

Filed under: Breast Cancer on April 17th, 2008